GlassScriptPhysician profile
Keith R Davis
NPI 1235129859
$3,172.90
in general payments reported to CMS, 2019-2025
34 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $392 · 2021: $942 · 2022: $712 · 2023: $267 · 2024: $95.69 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.70 | 2019-2023 | Liletta |
| Medical Device Business Services, INC. | $205.59 | 2021-2025 | Vistaseal |
| Therapeuticsmd, INC. | $192.44 | 2019-2022 | |
| Novo Nordisk INC | $176.22 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Hologic Sales and Service, LLC | $172.18 | 2019-2025 | Novasure |
| Ethicon US, LLC | $154.07 | 2021-2022 | |
| Lupin INC. | $151.98 | 2019-2020 | |
| Astellas Pharma US INC | $148.82 | 2020-2025 | Veozah |
| Myovant Sciences INC. | $144.24 | 2021-2022 | |
| Exeltis, USA INC. | $103.22 | 2020-2023 | Slynd |
| Davol INC. | $91.40 | 2022 | |
| Organon LLC | $88.28 | 2021-2023 | Nexplanon |
| Pfizer INC. | $84.34 | 2020-2023 | |
| Daiichi Sankyo INC. | $66.33 | 2019-2020 | |
| Amgen INC. | $59.89 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $55.26 | 2022 | |
| Mayne Pharma Commercial LLC | $54.38 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.21 | 2021-2022 | |
| Aspira Women'S Health INC | $50.00 | 2021 | |
| Merck Sharp & Dohme LLC | $40.75 | 2019-2021 | |
| Avion Pharmaceuticals | $37.97 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $37.71 | 2023 | Myfembree, Gemtesa |
| Medtronic, INC. | $36.04 | 2022 | |
| Baxter Healthcare | $32.10 | 2024 | Perclot |
| Millicent US INC | $31.53 | 2025 | Intrarosa, Femlyv |
| Coopersurgical, INC. | $30.41 | 2021-2025 | Paragard T 380a |
| Axonics, INC. | $28.26 | 2023 | Bulkamid, Axonics |
| Biogen, INC. | $28.13 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $27.07 | 2019-2020 | |
| Dysis Medical, INC. | $16.38 | 2022 | |
| Evofem Biosciences, INC. | $15.23 | 2021 | |
| Channel Medsystems, INC. | $14.68 | 2023 | |
| Mylan Pharmaceuticals INC. | $14.60 | 2022 | |
| Duchesnay USA Incorporated | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.